-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51

Benzinga·11/05/2026 13:44:01
Listen to the news
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.